PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains

Cancer Research

Volumn 73, Issue 11, 2013, Pages 3336-3346

  Picaud, Sarah ^a   Da Costa, David ^b   Thanasopoulou, Angeliki ^e   Filippakopoulos, Panagis ^a   Fish, Paul V ^d   Philpott, Martin ^a   Fedorov, Oleg ^a   Brennan, Paul ^a   Bunnage, Mark E ^d   Owen, Dafydd R ^d   Bradner, James E ^g,h   Taniere, Philippe ^c   O'Sullivan, Brendan ^c   Müller, Susanne ^a   Schwaller, Juerg ^e   Stankovic, Tatjana ^b   Knapp, Stefan ^a,f  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^f GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL LYSINE; AURORA B KINASE; BROMO AND EXTRA TERMINAL PROTEIN; HISTONE H3; HISTONE H3S10; JQ1 INHIBITOR; LYSINE; NUCLEAR PROTEIN; PIF 1 INHIBITOR; PROTEIN BRD2; PROTEIN BRD4; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR HOXA9; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL POPULATION; CHILD; CHROMATIN; CLONOGENESIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOWN REGULATION; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HISTONE ACETYLATION; HOX GENE; HOXA9 GENE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN TARGETING; SCHOOL CHILD;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CHILD; DOWN-REGULATION; HUMANS; MICE; MICE, INBRED NOD; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; PHOSPHORYLATION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878565710     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3292     Document Type: Article

References (46)

1. Mujtaba S, He Y, Zeng L, Farooq A, Carlson JE, Ott M, et al. Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol Cell 2002;9:575-86.
2. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012;149:214-31.
3. Muller S, Filippakopoulos P, Knapp S. Bromodomains as therapeutic targets. Expert Rev Mol Med 2011;13:e29.
4. Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999;399:491-6.
5. Owen DJ, Ornaghi P, Yang JC, Lowe N, Evans PR, Ballario P, et al. The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. Embo J 2000;19: 6141-9.
6. Moriniere J, Rousseaux S, Steuerwald U, Soler-Lopez M, Curtet S, Vitte AL, et al. Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 2009;461:664-8.
7. Dey A, Mochizuki K, Ozato K. Reduced expression of bromodomain protein Brd4 impedes Rb inactivation add S phase entry. Mol Biol Cell 2004;15:254a-a.
8. French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 2012;7:247-65.
9. Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, et al. c-Myc regulates transcriptional pause release. Cell 2010;141:4323-445.
10. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature 2010;468:1067-73.
11. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-17.
12. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478:524-28.
13. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, et al. Inhibition ofBETrecruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011;478:529-33.
14. Dey A, Chitsaz F, Abbasi A, Misteli T, Ozato K. The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci U S A 2003;100:8758-63.
15. Dey A, Nishiyama A, Karpova T, McNally J, Ozato K. Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Mol Biol Cell 2009;20:4899-909.
16. Andrews PD, Knatko E, Moore WJ, Swedlow Jr. Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol 2003;15:672-83.
17. Nezi L, Musacchio A. Sister chromatid tension and the spindle assembly checkpoint. Curr Opin Cell Biol 2009;21:785-95.
18. Lampson MA, Cheeseman IM. Sensing centromere tension: Aurora B and the regulation of kinetochore function. Trends Cell Biol 2011;21: 133-40.
19. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010; 10:825-41.
20. Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W. Aurora kinase inhibitors-rising stars in cancer therapeutics? Mol Cancer Ther 2010;9:268-78.
21. Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009;15:67-78.
22. Dey A, Ellenberg J, Farina A, Coleman AE, Maruyama T, Sciortino S, et al. A bromodomain protein, MCAP, associates with mitotic chromosomesandaffects G(2)-to-M transition.Mol Cell Biol 2000;20:6537-49.
23. Fish PV, Filippakopoulos P, Bish G, Brennan PE, Bunnage ME, Cook AS, et al. Identification of a chemical probe for bromo and extra Cterminal bromodomain inhibition through optimization of a fragmentderived hit. J Med Chem 2012;55:9831-7.
24. Fedorov O, Marsden B, Pogacic V, Rellos P, Muller S, Bullock AN, et al. Asystematic interactionmapof validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A 2007;104:20523-8.
25. Rich RL, Myszka DG. Higher-throughput, label-free, real-time molecular interaction analysis. Anal Biochem 2007;361:1-6.
26. Drexler HG, Quentmeier H, MacLeod RA. Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations. Leukemia 2004;18:227-32.
27. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011;108:16669-74.
28. Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 1996;382:511-7.
29. Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 1999;19:4672-83.
30. Hermeking H, Rago C, Schuhmacher M, Li Q, Barrett JF, Obaya AJ, et al. Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A 2000;97:2229-34.
31. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435: 839-43.
32. Careta FP, Gobessi S, Panepucci RA, Bojnik E, de Oliveira FM, Matos DM, et al. The Aurora A and B kinases are upregulated in bone marrowderived chronic lymphocytic leukemia cells and represent potential therapeutic targets. Haematologica 2012;97:1246-54.
33. Nagai K, Ochi T, Fujiwara H, An J, Shirakata T, Mineno J, et al. Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity. Blood 2012;119:368-76.
34. Bebbington D, Binch H, Charrier JD, Everitt S, Fraysse D, Golec J, et al. The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett 2009;19:3586-92.
35. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, et al. VX-680, a potent and selective smallmolecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-7.
36. Elkins JM, Santaguida S, Musacchio A, Knapp S. Crystal structure of human aurora B in complex with INCENP and VX-680. J Med Chem 2012;55:7841-8.
37. Kitzen JJ, de Jonge MJ, Verweij J. Aurora kinase inhibitors. Crit Rev Oncol Hematol 2010;73:99-110.
38. Sauvageau G, Lansdorp PM, Eaves CJ, Hogge DE, Dragowska WH, Reid DS, et al. Differential expression of homeobox genes in functionally distinct CD34+subpopulations of human bone marrow cells. Proc Natl Acad Sci U S A 1994;91:12223-7.
39. Calvo KR, Sykes DB, Pasillas MP, Kamps MP. Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1. Oncogene 2002;21:4247-56.
40. Shah N, Sukumar S. The Hox genes and their roles in oncogenesis. Nat Rev Cancer 2010;10:361-71.
41. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
42. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 1998;17:3714-25.
43. You J, Li Q, Wu C, Kim J, Ottinger M, Howley PM. Regulation of aurora B expression by the bromodomain protein Brd4. Mol Cell Biol 2009; 29:5094-103.
44. Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop JM. Therapeutic potential of a synthetic lethal interaction between the MYC protooncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci U S A 2010;107:13836-41.
45. Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 2004;64:3103-11.
46. Lassmann S, Weis R, Makowiec F, Roth J, Danciu M, Hopt U, et al. Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal-and microsatellite-unstable sporadic colorectal carcinomas. J Mol Med 2007; 85:293-304.